In 2023, malaria caused nearly 6 lakh deaths, with 95% occurring in Africa.
A trial in Kenya (BOHEMIA) showed that ivermectin reduced malaria cases by 26% in children aged 5-15.
A trial in Guinea-Bissau (MATAMAL) found no significant difference in malaria prevalence with the addition of ivermectin to an existing malaria treatment program.
Ivermectin kills mosquitoes after they bite humans, regardless of time or location, offering an advantage over traditional methods.
Detailed Insights:
Malaria control efforts have stalled recently after progress between 2000-2015, but India has reduced malaria cases by over 80% in the last decade.
Ivermectin, an endectocide, has been used since the 1970s against river blindness and lymphatic filariasis, and has shown potential in killing mosquitoes that bite treated individuals.
The BOHEMIA trial in Kwale County, Kenya, administered ivermectin or albendazole monthly for three months starting in October 2023, and found a significant reduction in malaria cases in the ivermectin group.
The MATAMAL trial in Guinea-Bissau involved over 25,000 people and tested the addition of ivermectin to a malaria treatment program using dihydroartemisinin-piperaquine, but found no significant difference in malaria prevalence.
Concerns exist regarding potential ivermectin resistance in mosquitoes and other parasites due to its widespread use in veterinary medicine and for treating conditions like scabies and lice.
Researchers are exploring strategies to mitigate resistance, including longer-lasting formulations, higher doses, and combining ivermectin with malaria vaccines or genetically modified mosquitoes.
Key Concepts Involved:
Endectocide: A systemic insecticide that works from inside the human body.
Malaria: A mosquito-borne infectious disease affecting humans and other animals.
Vector Control: Methods used to limit or eradicate the mosquitoes or other vectors that transmit disease pathogens.